best365体育_首頁(欢迎您)

知识产权

相关产品	专利名称	专利持有人	专利编号	注册司法权区	申请日期	到期日
HLX01 HLX02 HLX03 HLX04	用于CHO细胞DNA残留检测的试剂盒及其使用方法	best365体育	CN201110066745.4	中国	2011-03-18	2031-03-17
HLX01 HLX02 HLX03 HLX04	探针法检测CHO细胞DNA含量的方法	best365体育	CN201110099204.1	中国	2011-04-20	2031-04-19
HLX07	抗表皮生长因子受体(EGFR)抗体抗表皮生长因子受体(EGFR)抗体	汉霖生技汉霖生技	PCT/US2015/033402 TW104117520	中国、美国、欧洲、中国香港澳大利亚、日本、韩国中国台湾	2015-05-29 2015-05-29	2035-05-29 2035-05-29
HLX10	抗PD-1抗体抗PD-1抗体	best365体育美商汉霖；汉霖生技	PCT/ US2017/050851 TW106131824	澳大利亚、巴西、加拿大、中国、欧洲、日本、韩国、印尼、印度、马来西亚、菲律宾、俄罗斯、泰国、美国、南非中国台湾	2017-09-09 2017-09-15	2037-09-09 2037-09-15
HLX20	抗PD-L1抗体及变体抗PD-L1抗体及变体	best365体育美商汉霖; 汉霖生技	PCT/ US2017/056689 TW106137352	澳大利亚、巴西、加拿大、中国、欧洲、日本、韩国、印度、俄罗斯、美国、南非台湾	2017-10-14 2017-10-30	2037-10-14 2037-10-30

科学论文

Shi, Y., Song, Y., Qin, Y. et al. A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma. J Hematol Oncol 13, 38 (2020).
J Hematol Oncol
Zhu, X., Ding, Y., Yu, Y. et al. A Phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX02 to reference CN- and EU-sourced trastuzumab in healthy subjects. Cancer Chemother Pharmacol (2020).
Cancer Chemother Pharmacol
Poster: Xu, B. et al. HLX02, a China-manufactured trastuzumab biosimilar versus EU-sourced trastuzumab: Results of a global phase 3, randomized, double-blind efficacy and safety comparative study in metastatic breast cancer. European Journal of Cancer, 2020, 138 (suppl. 1), S68.
EBCC 2020
Poster: Zhang, Q. et al. 287P Efficacy, safety and pharmacokinetics of a proposed trastuzumab biosimilar HLX02 compared with trastuzumab in metastatic breast cancer: A global phase III study. Annals of Oncology, 2020, 31 (suppl_4), S356.
ESMO 2020
Oral: Binghe Xu, M.D., Ph.D. China-Manufactured Trastuzumab Biosimilar HLX02: Efficacy, Safety and Pharmacokinetics Comparison to Reference TZB in a Phase 3 Metastatic Breast Cancer Study. Award of excellence, Third Prize Winner.
CSCO 2020
Poster: Zhang, J. et al. Efficacy, Safety and Immunogenicity of the Biosimilar HLX03 Compared with Adalimumab in Chinese Patients with Moderate to Severe Plaque Psoriasis: A Randomised, Double-blind, Phase 3 Equivalence Study.
EADV 2020